相关实验视频
Updated: Feb 7, 2026

09:45
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
7.5K
甲福明通过 lncRP11-242D8.1 抑制非小细胞肺癌
Xinmin Tian1, Zhixiong Qiao2, Yan Ma3
1Department of Cardiac and Major Vascular Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China.
Archives of biochemistry and biophysics
|February 5, 2026
概括
糖尿病药物梅特福林在治疗非小细胞肺癌 (NSCLC) 中表现有前途,通过增加 lncRP11-242D8.1 长非编码RNA. 这种机制有助于减少炎症并促进癌细胞死亡.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非小细胞肺癌 (NSCLC) 是癌症死亡的主要原因.
- 长非编码RNAs (lncRNAs) 在NSCLC的发展和进展中发挥着关键作用.
- 广泛使用的抗糖尿病药物梅特福明已经显示出潜在的抗癌特性.
研究的目的:
- 为了研究甲福明对NSCLC的抑制作用.
- 探索甲胺在NSCLC中调节lncRP11-242D8.1的表达中的作用.
- 阐明在NSCLC中甲福明的抗癌作用背后的分子机制.
主要方法:
- 使用免疫光学,RT-qPCR和ELISA评估炎症和亡.
- 在实验室中通过CCK8,伤愈合,Transwell,殖民地形成和流细胞计测试对甲胺对NSCLC细胞系 (H1299) 的影响进行评估.
- 结合生物信息学分析和分子实验,以确定甲胺和lncRP11-242D8.1.1.之间的相互作用.
主要成果:
- lncRP11-242D8.1的低表达与炎症增加,亡减少和NSCLC的预后不佳相关.
- 在H1299细胞模型中,甲胺治疗逆转了这些趋势,表明对NSCLC进展有抑制作用.
- 观察到metformin对lncRP11-242D8.1的升调,这表明它参与了metformin的治疗作用.
结论:
- 甲胺通过上调 lncRP11-242D8.1 的表达来对NSCLC 产生治疗作用.
- 甲福明对lncRP11-242D8.1的上调导致NSCLC的炎症抑制和亡促进.
- 这项研究为甲福明的抗癌活性提供了新的机制性见解,表明其作为NSCLC临床治疗策略的潜力.
相关概念视频
Feedback Inhibition
57.2K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.2K
Lung Capacity
56.4K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Enzyme Inhibition
92.6K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.6K
Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
Cancer Cell Migration through Invadopodia
3.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.3K
Adaptive Mechanisms in Cancer Cells
7.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K

